The core therapeutic potential of IL-37 in asthma stems from its ability to intervene in the pathogenic mechanisms of asthma, including the inhibition of pro-inflammatory cytokine production, the reduction of cytokines that impair airway epithelial barrier function, and the prevention of airway remodeling. This evidence concerns the gene IL37 and asthma.